Taken together, these studies provide evidence that the development of experimental AIP following repeated poly(I:C) administration is initiated by TLR3+ cDCs producing type I IFNs, CXCL9, and CXCL10. The gene discussed is CXCL9; the disease is autoimmune pancreatitis.